MarketPulse

capital-intensive

5 articles
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Rivian Edges Lucid in EV Showdown as Production Reality Reshapes Startup Race

Rivian outpaces Lucid with achieved production scale and positive margins, while Lucid struggles with execution. Both remain unprofitable but Rivian's trajectory appears stronger.
TSLALCIDRIVNelectric vehiclescapital-intensive
The Motley FoolThe Motley Fool··Sean Williams

SpaceX IPO Plans Draw Skepticism Over $1.75T Valuation and Execution Risks

SpaceX confidentially files for IPO with $1.75 trillion valuation, seeking $50-75B. Analyst raises concerns over valuation metrics and leadership execution track record.
METATSLAASTSvaluationIPO
BenzingaBenzinga··Erica Kollmann

Micro-Cap Jet AI Launches $5M Buyback Amid Speculative AI Data Center Pivot

Jet AI announces $5M buyback as it shifts from aviation to AI data centers. Stock surges 11.8% on speculation, but execution risks loom for the $11M market cap firm.
JTAIexecution riskdata center
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Lucid's 98% Stock Collapse Masks Deeper Profitability Crisis

Lucid stock down 98% from peak despite production gains. Company lost money per vehicle in 2025, unlike rival Rivian, limiting appeal to risk-tolerant investors.
TSLALCIDRIVNprofitabilityelectric vehicles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Expands Spyre Therapeutics Position as Stock Climbs 63% YoY

Commodore Capital increases Spyre Therapeutics stake to $78.24M as stock surges 63% YoY. Biotech firm has $757M cash and expects Phase 2 data in 2026.
ALKSSYRERLAYXENEbiotechbalance sheet strength